.jpg)
The aims of the project.
Perso-Med is an Interreg IVA FWVL project, lead by Eurasanté (France) and FlandersBio (Belgium).
This project is an opportunity for companies from Nord-Pas de Calais and Flanders to enhance their competitiveness and innovative capacity on a common theme: the personalised medicine.
The activity sectors concerned by this project are therapeutics and diagnostics.
Objectives of PERSO-MED project
Stimulate and facilitate cross-border R&D partnerships among personalized medicine players from the participating regions.
Set up a long-lasting cross-border support framework to assist personalised medicine players by launching a non ERDF funded cross-border “Call for proposals”.
Supply Personalized Medicine Players with necessary tools to tackle Standards and Regulatory issues.
Supply Personalized Medicine Players with necessary information on the foreseen impact of personalized medicine on healthcare systems.
Join us on Linked in
Add one or more tags to refine your search :
■ Special Interest Group num 3 in Lille
Thursday, September 26th 2013 from 1.30 pm to 6.30 pm
« Institut Gernez-Rieux, amphi B »
CHRU of Lille, rue du docteur Schweitzer, 59037 Lille
Program
|
PERSONALIZED MEDICINE – ONCOLOGY: diagnostic, targeted therapy and imaging |
||
|
1.30 |
Registration & refreshments |
|
|
1.45 |
Welcome and overview of the Persomed project |
Sophie GENY (Eurasanté, France) |
|
2.00 |
BICel, innovative platform for cellular imaging in oncology research |
Frank LAFONT (BioImaging Center, France) |
|
2.20 |
Characterization of predictive model in oncology by imaging mass spectrometry |
Jonathan STAUBER (Imabiotech, France) |
|
2.40 |
Activated hormone receptors and Breast cancer |
Erard GILLES (INVIVIS Pharmaceuticals, Bridgewater, USA) & Jacques BONNETERRE (Centre Oscar Lambret, Lille) |
|
3.00 |
Validation of the use of a peptide vaccine in Nasopharyngeal Carcinoma: from in vitro experiments to the proposal of new therapeutic trials |
Nadira DELHEM (Immunoregulation of virus-induced cancers, France) |
|
3.20 |
Innovative multiplex solutions for diagnostic |
Vianney SOUPLET (Innobiochips, France) |
|
3.40 |
Good and bad in cancer inflammation: implication for therapy and diagnosis |
Massimiliano MAZZONE (University of Leuven, Belgium) |
|
4.00 |
Refreshments and discussion |
|
|
4.20 |
p53 Reactivation therapy in cancer |
Chris MARINE (University of Leuven, Belgium) |
|
4.40 |
Building a cytometric screening platform to facilitate discovery in fundamental cell death research |
Vera GOOSENS (University of Ghent, Belgium) |
|
5.00 |
Targeted re-sequencing of actionable genes |
Dirk POLLET (Multiplicom, Belgium)
|
|
5.30 |
CLIC-IMAGING: MALDI imaging and proteomics platform for oncology |
Michel SALZET (PRISM laboratory - EA 4550, France) |
|
6.00 |
Cocktail & discussion |
|
|
6.30 |
Closing |
|
To register click here or send an e-mail at sgeny@eurasante.com
